EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial

Narges Sharifzadeh, Ali Ghasemi, Jalil Tavakol Afshari, Fatemeh Moharari, Atefeh Soltanifar, Ali Talaei, Hamid Reza Pouryousof, Mahsa Nahidi iD, Mohammad Reza Fayyazi Bordbar, Maliheh Ziaee

Asia-Pacific Psychiatry · 2021-06 · 13 (2)

DOI: 10.1111/appy.12445 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Asia-Pacific Psychiatry, online erschienen am 04.11.2020. Verfasst von Narges Sharifzadeh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Autistic Disorder. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Mashhad University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to determine the safety and efficacy of treatment with autologous bone marrow mesenchymal stem cell (BMMSCs) compared with the routine treatment in children with autism spectrum disorder (ASD).

Methods

In this ethically approved randomized controlled trial, 32 ASD children aged 5‐15 years were randomly assigned to receive either autologous BMMSC plus rehabilitation therapy and risperidone (intervention group) or rehabilitation therapy and risperidone (control group). Autologous BMMSCs were intrathecally injected in the intervention group twice in 4 weeks. Patients were assessed using childhood autism rating scale (CARS), Gilliam autism rating scale‐second edition (GARS‐II), and clinical global impression (CGI) at the baseline, as well as 6 and 12 months after intervention.

Results

Overall, 32 patients in two groups of intervention (n = 14) and control (n = 18) completed the study, of which 27 (84.4%) were male. Mean age was 9.50 ± 2.14 years. The improvements in CARS total score, GARS‐II autism index, and CGI global improvement showed no significant differences between the groups over 12 months. However, the main effect for time*group interaction was significant regarding the CGI‐severity of illness, showing a significantly more pronounced improvement in the intervention group (F = 6.719; P = .002).

Discussion

Intrathecal injection of autologous BMMSCs seems to be safe and feasible, but has limited clinical efficacy in treatment of children with ASD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autism Spectrum DisorderAutistic DisorderBone MarrowCell- and Tissue-Based TherapyChildHumansMaleRisperidone

Stichwörter der Autor:innen

augmentation therapyautism spectrum disorderautologous bone marrow stem cellmesenchymal stem cell

Substanzen

Risperidone

Autor:innen und Institutionen

  • Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Pediatric Hematology and Oncology, Dr Sheikh Pediatric Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • General Directorate of Welfare, State Welfare Organization of Razavi Khorasan, Mashhad, Iran.
  • Department of Community Medicine, School of Medicine, Social Determinants of Health Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.

ORCID-Profile: Mahsa Nahidi

Förderung

  • Mashhad University of Medical Sciences

Zitieren

APA

Sharifzadeh, N., Ghasemi, A., Tavakol Afshari, J., Moharari, F., Soltanifar, A., Talaei, A., Pouryousof, H. R., Nahidi, M., Fayyazi Bordbar, M. R., & Ziaee, M. (2021). Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial. Asia-Pacific Psychiatry, 13(2). https://doi.org/10.1111/appy.12445

Vancouver

Sharifzadeh N, Ghasemi A, Tavakol Afshari J, Moharari F, Soltanifar A, Talaei A, et al. Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial. Asia-Pacific Psychiatry. 2021;13(2). doi:10.1111/appy.12445

BibTeX
@article{Sharifzadeh2021,
  author = {Sharifzadeh, Narges and Ghasemi, Ali and Tavakol Afshari, Jalil and Moharari, Fatemeh and Soltanifar, Atefeh and Talaei, Ali and Pouryousof, Hamid Reza and Nahidi, Mahsa and Fayyazi Bordbar, Mohammad Reza and Ziaee, Maliheh},
  title = {Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial},
  journal = {Asia-Pacific Psychiatry},
  year = {2021},
  volume = {13},
  number = {2},
  doi = {10.1111/appy.12445}
}
Kostenlos starten →